FDA Approves Fulvestrant in Combination With Abemaciclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

November 15, 2017 – Today, the U.S. Food and Drug Administration (FDA) approved a new indication for fulvestrant, expanding the drug’s approved use to include combined therapy with abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, for the treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in women with disease progression after endocrine therapy. Fulvestrant was also approved today by the European … (leggi tutto)